NCT04157985 2025-12-11Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid TumorsUniversity of PittsburghPhase 3 Completed161 enrolled
NCT05600309 2025-11-26A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension StudyMerck Sharp & Dohme LLCPhase 3 Completed94 enrolled 15 charts
NCT02563002 2024-10-03KEYNOTE-177Merck Sharp & Dohme LLCPhase 3 Completed307 enrolled 16 charts 3 FDA